{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:31:24Z","timestamp":1725409884865},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,3]]},"DOI":"10.7759\/cureus.68518","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T11:08:16Z","timestamp":1725361696000},"source":"Crossref","is-referenced-by-count":0,"title":["Successful Treatment of Refractory Cutaneous Manifestations of Dermatomyositis With Intravenous Immunoglobulin: A Case Report"],"prefix":"10.7759","author":[{"given":"Yousif B","family":"Aldoseri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid B","family":"Aldoseri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.11.005","article-title":"The clinical features, diagnosis and classification of dermatomyositis","volume":"48-9","author":"Iaccarino L","year":"2014","unstructured":"Iaccarino L, Ghirardello A, Bettio S, Zen M, Gatto M, Punzi L, Doria A. The clinical features, diagnosis and classification of dermatomyositis. J Autoimmun. 2014, 48-9:122-7. 10.1016\/j.jaut.2013.11.005","journal-title":"J Autoimmun"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.1.7","article-title":"Treatment of dermatomyositis and polymyositis","volume":"41","author":"Choy EH","year":"2002","unstructured":"Choy EH, Isenberg DA. Treatment of dermatomyositis and polymyositis. Rheumatology (Oxford). 2002, 41:7-13. 10.1093\/rheumatology\/41.1.7","journal-title":"Rheumatology (Oxford)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.55561\/ajhr.v3i1.149","article-title":"Combination therapy of prednisone, azathioprine, and hydroxychloroquine in patient with dermatomyositis","volume":"3","author":"Swanenghyun G","year":"2024","unstructured":"Swanenghyun G, Yuniaswan AP. Combination therapy of prednisone, azathioprine, and hydroxychloroquine in patient with dermatomyositis. Asian J Heal Res. 2024, 3:52-5. 10.55561\/ajhr.v3i1.149","journal-title":"Asian J Heal Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1979.04010100055023","article-title":"Treatment of dermatomyositis with methotrexate and prednisone","volume":"115","author":"Giannini M","year":"1979","unstructured":"Giannini M, Callen JP. Treatment of dermatomyositis with methotrexate and prednisone. Arch Dermatol. 1979, 115:1251-2. 10.1001\/archderm.1979.04010100055023","journal-title":"Arch Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31821072b7","article-title":"Successful use of rituximab in recalcitrant skin predominant dermatomyositis","volume":"17","author":"Joshi N","year":"2011","unstructured":"Joshi N, Nautiyal A, Davies PG. Successful use of rituximab in recalcitrant skin predominant dermatomyositis. J Clin Rheumatol. 2011, 17:111-2. 10.1097\/RHU.0b013e31821072b7","journal-title":"J Clin Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez572","article-title":"Anti-TIF1-\u03b3 autoantibodies: warning lights of a tumour autoantigen","volume":"59","author":"De Vooght J","year":"2020","unstructured":"De Vooght J, Vulsteke JB, De Haes P, Bossuyt X, Lories R, De Langhe E. Anti-TIF1-\u03b3 autoantibodies: warning lights of a tumour autoantigen. Rheumatology (Oxford). 2020, 59:469-77. 10.1093\/rheumatology\/kez572","journal-title":"Rheumatology (Oxford)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew396","article-title":"Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab","volume":"56","author":"Aggarwal R","year":"2017","unstructured":"Aggarwal R, Loganathan P, Koontz D, Qi Z, Reed AM, Oddis CV. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology (Oxford). 2017, 56:247-54. 10.1093\/rheumatology\/kew396","journal-title":"Rheumatology (Oxford)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13607","article-title":"Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis","volume":"43","author":"Galimberti F","year":"2018","unstructured":"Galimberti F, Kooistra L, Li Y, Chatterjee S, Fernandez AP. Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis. Clin Exp Dermatol. 2018, 43:906-12. 10.1111\/ced.13607","journal-title":"Clin Exp Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1385\/CRIAI:29:3:173","article-title":"Intravenous immunoglobulin: adverse effects and safe administration","volume":"29","author":"Orbach H","year":"2005","unstructured":"Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005, 29:173-84. 10.1385\/CRIAI:29:3:173","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-007-0013-0","article-title":"Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis","volume":"18","author":"Saito E","year":"2008","unstructured":"Saito E, Koike T, Hashimoto H, et al.. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol. 2008, 18:34-44. 10.1007\/s10165-007-0013-0","journal-title":"Mod Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key366","article-title":"Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib","volume":"58","author":"Moghadam-Kia S","year":"2019","unstructured":"Moghadam-Kia S, Charlton D, Aggarwal R, Oddis CV. Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib. Rheumatology (Oxford). 2019, 58:1011-5. 10.1093\/rheumatology\/key366","journal-title":"Rheumatology (Oxford)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.10.023","article-title":"Refractory dermatomyositis responsive to anifrolumab","volume":"43","author":"Ang PS","year":"2023","unstructured":"Ang PS, Ezenwa E, Ko K, Hoffman MD. Refractory dermatomyositis responsive to anifrolumab. JAAD Case Rep. 2023, 43:27-9. 10.1016\/j.jdcr.2023.10.023","journal-title":"JAAD Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/245080-successful-treatment-of-refractory-cutaneous-manifestations-of-dermatomyositis-with-intravenous-immunoglobulin-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T11:08:19Z","timestamp":1725361699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/245080-successful-treatment-of-refractory-cutaneous-manifestations-of-dermatomyositis-with-intravenous-immunoglobulin-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.68518","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,3]]}}}